PULIKE(SH:603566)2024-04-25 10:22Financial Performance - The company's operating revenue for Q1 2024 was ¥235,489,193.20, representing a decrease of 23.27% compared to the same period last year[3] - The net profit attributable to shareholders was ¥27,307,052.31, down 57.36% year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥26,535,800.53, a decrease of 56.10% compared to the previous year[3] - The company reported a net profit of CNY 30,309,849.97 for Q1 2024, compared to a net profit of CNY 65,853,381.34 in Q1 2023, indicating a decline in profitability[20] - The net profit for Q1 2024 is CNY 27,307,052.31, a decrease of 57.4% compared to CNY 64,039,214.39 in Q1 2023[21] - Operating profit for Q1 2024 is CNY 31,185,610.68, down from CNY 75,288,713.97 in the same period last year, representing a decline of 58.6%[21] - The total profit for Q1 2024 is CNY 31,064,720.71, down from CNY 75,365,391.43 in Q1 2023, reflecting a decrease of 58.8%[21] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥4,394,457.00, reflecting a decline of 113.66%[3] - Cash flow from operating activities for Q1 2024 is negative at CNY -4,394,457.00, compared to a positive CNY 32,169,320.98 in Q1 2023[25] - The cash flow from investment activities is negative at CNY -95,695,591.48 for Q1 2024, compared to a positive CNY 6,868,985.95 in Q1 2023[25] - The total cash and cash equivalents at the end of Q1 2024 is CNY 193,951,219.06, a decrease from CNY 303,902,530.58 at the end of Q1 2023[26] - Cash and cash equivalents decreased to CNY 198,455,275.70 as of March 31, 2024, from CNY 317,214,603.27 at the end of 2023, indicating liquidity challenges[15] Revenue Breakdown - Revenue from the biological products segment was ¥167,801,488.57, down 9.64% year-on-year, with swine vaccines declining by 25.08%[5] - The revenue from chemical drugs was ¥53,983,997.26, a significant drop of 52.80% compared to the previous year[5] - The company reported a significant decrease in sales revenue from CNY 333,504,750.28 in Q1 2023 to CNY 242,447,918.40 in Q1 2024, a decline of 27.3%[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,205,137,124.84, a decrease of 1.75% from the end of the previous year[4] - Total assets as of March 31, 2024, were CNY 3,205,137,124.84, down from CNY 3,262,208,830.69 at the end of 2023[18] - Total liabilities decreased to CNY 471,723,911.92 as of March 31, 2024, from CNY 538,334,059.46 at the end of 2023, showing improved financial stability[17] Cost and Expenses - Total operating costs for Q1 2024 were CNY 205,179,343.23, down 14.9% from CNY 241,057,359.58 in Q1 2023[20] - Gross profit margin for Q1 2024 was approximately 10.8%, compared to 21.3% in Q1 2023[20] - Research and development expenses increased to CNY 20,460,399.77 in Q1 2024, up from CNY 17,441,000.70 in Q1 2023, reflecting a focus on innovation[20] Other Financial Metrics - The company reported a basic earnings per share of ¥0.08, down 57.89% from the same period last year[3] - Basic and diluted earnings per share for Q1 2024 are both CNY 0.08, down from CNY 0.19 in Q1 2023[22] - The weighted average return on net assets was 1.00%, a decrease of 1.26 percentage points[3] - The company experienced a 37.44% decrease in cash and cash equivalents, primarily due to increased payments for engineering projects[8] - Inventory levels increased to CNY 187,061,605.45 as of March 31, 2024, from CNY 183,619,075.92 at the end of 2023, suggesting potential overstocking[16] - The total cash inflow from investment activities in Q1 2024 is CNY 298,979,127.45, down from CNY 872,264,903.19 in Q1 2023, a decrease of 65.7%[25]